Page last updated: 2024-11-13

angiogenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

angiogenin: human tumor protein which stimulates growth of blood vessels; contains 123 amino acids; member of the pancreatic ribonuclease superfamily; MW 14,400 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133112768
MeSH IDM0134380

Synonyms (1)

Synonym
angiogenin

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
") administration of 15, 30, and 60 mg kg(-1) neamine, the pharmacokinetic parameters were as follows: AUC(0-t), 9,398."( Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.
An, S; Hu, G; Liu, Y; Wu, Y; Zhang, X, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
"This study aimed to develop a gene delivery system using ultrasound-targeted microbubbles destruction (UTMD) combined with nuclear localization signal (NLS) and investigate its efficacy and safety for therapeutic angiogenesis in canine myocardial infarction (MI) model."( Enhancement of Angiogenesis by Ultrasound-Targeted Microbubble Destruction Combined with Nuclear Localization Signaling Peptides in Canine Myocardial Infarction.
Cao, S; Chen, J; Cui, J; Deng, Q; Hu, B; Jiang, N; Tan, T; Wang, Y; Zhou, Q, 2017
)
0.46
"Fifty MI dogs were randomly divided into 5 groups and transfected with Ang-1 gene plasmid: (i) group A: only injection of microbubbles and Ang-1 plasmid; (ii) group B: only UTMD mediated gene transfection; (iii) group C: UTMD combined with classical NLS mediated gene transfection; (iv) group D: UTMD combined with mutational NLS mediated transfection; and (v) group E: UTMD combined with classical NLS in the presence of a nucleus transport blocker."( Enhancement of Angiogenesis by Ultrasound-Targeted Microbubble Destruction Combined with Nuclear Localization Signaling Peptides in Canine Myocardial Infarction.
Cao, S; Chen, J; Cui, J; Deng, Q; Hu, B; Jiang, N; Tan, T; Wang, Y; Zhou, Q, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" Due to their polymeric structure, GSPs are poorly absorbed along the gastrointestinal tract and can reach the colon at high concentrations, allowing these chemicals to act as chemopreventive agents for colon cancer."( Grape seed proanthocyanidins inhibit colon cancer-induced angiogenesis through suppressing the expression of VEGF and Ang1.
Gao, J; Hu, L; Huang, S; Huang, T; Li, C; Li, Y; Liu, Y; Yang, N; Zhang, X; Zhao, J, 2012
)
0.38
" The bioavailability of neamine administered through intramuscular, subcutaneous, intraperitoneal and intragastric route was 14."( Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.
An, S; Hu, G; Liu, Y; Wu, Y; Zhang, X, 2015
)
0.42
"The bioavailability of neamine administered through extravascular routes was low."( Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.
An, S; Hu, G; Liu, Y; Wu, Y; Zhang, X, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" This suggests that a higher dosing frequency in order to maintain a therapeutic effect."( Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.
An, S; Hu, G; Liu, Y; Wu, Y; Zhang, X, 2015
)
0.42
" In experiments 1 and 2, granulosa cells from small (1 to 5 mm diameter) follicles and theca cells from large (8 to 22 mm diameter) follicles were cultured to evaluate the dose-response effect of recombinant human angiogenin on steroidogenesis."( Effects of angiogenin on granulosa and theca cell function in cattle.
Burress, AM; Dentis, JL; Schreiber, NB; Spicer, LJ, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (898)

TimeframeStudies, This Drug (%)All Drugs %
pre-199050 (5.57)18.7374
1990's146 (16.26)18.2507
2000's284 (31.63)29.6817
2010's355 (39.53)24.3611
2020's63 (7.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (1.28%)5.53%
Reviews74 (7.91%)6.00%
Case Studies9 (0.96%)4.05%
Observational2 (0.21%)0.25%
Other838 (89.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT01720628]86 participants (Actual)Observational2011-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]